腫瘤體內CRO市場規模、佔有率和成長分析：按服務類型、癌症類型、模型類型、應用、最終用戶、研究階段和地區分類 - 產業預測（2026-2033）

2024 年全球腫瘤領域體內 CRO 市值為 15 億美元，預計到 2025 年將成長至 16.2 億美元，到 2033 年將成長至 30.2 億美元，在預測期（2026-2033 年）內複合年成長率為 8.08%。

腫瘤領域的體內CRO（合約研究組織）市場正經歷顯著成長，這主要得益於對能夠有效預測臨床結果的轉化前臨床模型日益成長的需求。這種研究外包模式的演化也正在重塑CRO提供的服務，CRO正利用患者來源的異質骨移植和基因修飾小鼠模型，提供專注於體內療效、安全性和藥理學的服務。可靠的動物實驗數據在縮短研發週期和降低臨床風險方面發揮著至關重要的作用。隨著精準腫瘤學的不斷發展，對複雜模型的需求日益成長，生物技術公司正在採用先進的平台來檢驗標靶治療的療效。此外，將基於生物標記的研究設計與體內測試相結合，正在提升CRO的服務質量，有助於更早做出決策、最佳化腫瘤研發管線，並確保符合轉化相關性監管要求。

全球腫瘤領域體內CRO市場的主要促進因素

免疫學在臨床前模型中的創新，以及產品預測技術的進步，提高了合約研究組織 (CRO) 和生物製藥企業體內試驗的可靠性。這種可靠性的提升使 CRO 能夠提供更廣泛的腫瘤特異性體內試驗方案，這些方案與臨床研究目標更加契合。因此，CRO 預計將擴大其合約研究範圍，提升市場佔有率，並與生物製藥申辦者建立更牢固的夥伴關係。這一發展不僅促進了 CRO 服務外包的成長，也凸顯了在競爭激烈的全球市場中提供專業的腫瘤特異性體內試驗的戰略重要性。

全球腫瘤領域體內CRO市場面臨的限制因素

全球腫瘤領域體內CRO市場面臨許多挑戰，其中最主要的挑戰在於倫理和監管要求的複雜交織，這給相關機構帶來了沉重的營運負擔。此外，為了遵守各種動物福利和監管標準，還需要完善的合規體系、專業人員和維修的設施，這進一步加劇了這些機構的負擔。區域差異也使情況更加複雜，增加了跨國試驗的行政負擔，並阻礙了試驗方案的協調統一。這可能會使申辦者對特定的體內模型望而卻步。這些複雜因素提高了市場准入門檻，限制了試驗設計的速度和靈活性，最終阻礙了市場成長，儘管科學界對體內評估的需求仍然存在。

全球腫瘤領域體內CRO市場趨勢

在全球腫瘤CRO市場，整合轉化平台正成為日益成長的趨勢，服務供應商將體內藥理學、生物標記發現和計算建模相結合。這種整合旨在簡化腫瘤候選化合物的篩選流程，並加快決策速度。申辦方強調統一的資料流、標準化的方案和跨學科方法，以最大限度地減少從藥物發現到臨床前階段的碎片化。這種發展趨勢促進了更高級的合作和共同開發契約的達成，從而能夠簽訂長期服務合約並建立策略合作夥伴關係。因此，服務提供者正從一次性交易模式轉向合作夥伴關係，從而提高轉化研究的可預測性，並確保腫瘤項目的連續性。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球腫瘤領域體內CRO市場規模：依服務類型分類

• 臨床前腫瘤體內試驗
• 藥物動力學和動態研究
• 毒性測試
• 生物標記分析服務
• 影像和監測服務
• 藥物功效測試服務
• 其他

全球腫瘤領域體內CRO市場規模：依癌症類型分類

• 肺癌
• 乳癌
• 結腸癌
• 血癌
• 攝護腺癌
• 肝癌
• 其他

全球腫瘤領域體內CRO市場規模：依模型類型分類

• 小鼠模型
• 大鼠模型
• 斑馬魚模型
• 其他

全球腫瘤領域體內 CRO 市場規模：依應用領域分類。

• 藥物發現
• 臨床前開發
• 免疫腫瘤學調查
• 詳細的腫瘤學檢查
• 細胞與基因治療研究
• 其他

全球腫瘤領域體內CRO市場規模：依最終用戶分類

• 製藥公司
• 生技公司
• 學術研究機構
• 政府附屬研究機構
• 其他

全球腫瘤領域體內CRO市場規模：依研究階段分類

• 早期藥物發現研究
• IND申請準備考試
• 轉化研究

全球腫瘤領域體內CRO市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Charles River Laboratories
• Labcorp Drug Development
• ICON plc
• Evotec
• WuXi AppTec
• Pharmaron
• Crown Bioscience
• Taconic Biosciences
• The Jackson Laboratory
• Champions Oncology
• Eurofins Scientific
• Oncodesign Services
• Syneos Health
• Parexel International
• Inotiv
• Covance
• Horizon Discovery
• MBL International
• Creative Biolabs
• Xentech

結論與建議

Global Oncology Based In-Vivo CRO Market size was valued at USD 1.50 Billion in 2024 and is poised to grow from USD 1.62 Billion in 2025 to USD 3.02 Billion by 2033, growing at a CAGR of 8.08% during the forecast period (2026-2033).

The oncology-based in vivo Contract Research Organization (CRO) market is experiencing significant growth driven by the increasing demand for translational preclinical models that effectively predict clinical outcomes. This evolution in study outsourcing is reshaping the services provided by CROs, which focus on in vivo efficacy, safety, and pharmacology, utilizing patient-derived xenografts and genetically engineered mouse models. Reliable animal data play a crucial role in shortening development timelines and mitigating clinical risks. As precision oncology continues to evolve, the need for complex models intensifies, prompting biotech firms to adopt advanced platforms for validating targeted agents. Additionally, the integration of biomarker-driven trial designs with in vivo studies enhances CRO offerings, enabling earlier decision-making and optimizing oncology pipelines while addressing regulatory demands for translational relevance.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Oncology Based In-Vivo CRO market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Oncology Based In-Vivo CRO Market Segments Analysis

Global oncology based in-vivo CRO market is segmented by service type, cancer type, model type, application, end user, study phase and region. Based on by service type, the market is segmented into preclinical in-vivo oncology studies, pharmacokinetics & pharmacodynamics studies, toxicology studies, biomarker analysis services, imaging & monitoring services, drug efficacy testing services and others. Based on by cancer type, the market is segmented into lung cancer, breast cancer, colorectal cancer, hematological cancers, prostate cancer, liver cancer and others. Based on by model type, the market is segmented into mouse models, rat models, zebrafish models and others. Based on by application, the market is segmented into drug discovery, preclinical development, immuno-oncology research, precision oncology research, cell & gene therapy research and others. Based on by end user, the market is segmented into pharmaceutical companies, biotechnology companies, academic & research institutes, government research organizations and others. Based on by study phase, the market is segmented into early-stage discovery studies, IND-enabling studies and translational research studies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Oncology Based In-Vivo CRO Market

Innovations in immunology within preclinical models, coupled with advancements in product prediction, have enhanced the reliability of in-vivo testing for contract research organizations (CROs) and biopharmaceutical manufacturers. This heightened confidence enables CROs to present a broader array of in-vivo oncology options that align more closely with the goals of clinical research. As a result, CROs are poised to expand their market presence and foster stronger partnerships with biopharmaceutical sponsors through an expanded range of contract studies. This evolution not only supports the growth of outsourced CRO services but also underscores the strategic significance of providing specialized in-vivo oncology testing in a competitive global marketplace.

Restraints in the Global Oncology Based In-Vivo CRO Market

The Global Oncology Based In-Vivo CRO market faces significant challenges due to the intricate web of ethical and regulatory requirements that create an operational strain on these organizations. The need for comprehensive compliance frameworks, expert personnel, and modified facilities to align with varying animal welfare and study oversight standards increases this burden. Disparities across different jurisdictions further complicate matters, leading to greater administrative demands for multinational studies and hindering the harmonization of protocols, which can deter sponsors from exploring certain in vivo models. This complexity raises entry barriers and restricts the speed and adaptability of study designs, ultimately hampering market growth despite the ongoing scientific need for in vivo evaluations.

Market Trends of the Global Oncology Based In-Vivo CRO Market

The Global Oncology Based In-Vivo CRO market is increasingly witnessing a trend towards integrated translational platforms, where service providers are combining in vivo pharmacology, biomarker discovery, and computational modeling. This consolidation is aimed at streamlining oncology candidate selection processes and expediting decision-making. Sponsors are favoring unified data flows, standardized protocols, and multidisciplinary approaches to minimize fragmentation in the transition from discovery to pre-clinical phases. This evolution encourages more sophisticated collaborations and co-development agreements, enabling longer service contracts and fostering strategic alliances. As a result, providers are shifting from transactional models to collaborative partnerships, enhancing translational predictability and ensuring continuity in oncology programs.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Oncology Based In-vivo CRO Market Size by Service Type & CAGR (2026-2033)

• Market Overview
• Preclinical In-vivo Oncology Studies
• Pharmacokinetics & Pharmacodynamics Studies
• Toxicology Studies
• Biomarker Analysis Services
• Imaging & Monitoring Services
• Drug Efficacy Testing Services
• Others

Global Oncology Based In-vivo CRO Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Hematological Cancers
• Prostate Cancer
• Liver Cancer
• Others

Global Oncology Based In-vivo CRO Market Size by Model Type & CAGR (2026-2033)

• Market Overview
• Mouse Models
• Rat Models
• Zebrafish Models
• Others

Global Oncology Based In-vivo CRO Market Size by Application & CAGR (2026-2033)

• Market Overview
• Drug Discovery
• Preclinical Development
• Immuno-oncology Research
• Precision Oncology Research
• Cell & Gene Therapy Research
• Others

Global Oncology Based In-vivo CRO Market Size by End User & CAGR (2026-2033)

• Market Overview
• Pharmaceutical Companies
• Biotechnology Companies
• Academic & Research Institutes
• Government Research Organizations
• Others

Global Oncology Based In-vivo CRO Market Size by Study Phase & CAGR (2026-2033)

• Market Overview
• Early-stage Discovery Studies
• IND-enabling Studies
• Translational Research Studies

Global Oncology Based In-vivo CRO Market Size & CAGR (2026-2033)

• North America (By Service Type, By Cancer Type, By Model Type, By Application, By End User, By Study Phase)
  • US
  • Canada
• Europe (By Service Type, By Cancer Type, By Model Type, By Application, By End User, By Study Phase)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (By Service Type, By Cancer Type, By Model Type, By Application, By End User, By Study Phase)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (By Service Type, By Cancer Type, By Model Type, By Application, By End User, By Study Phase)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (By Service Type, By Cancer Type, By Model Type, By Application, By End User, By Study Phase)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Charles River Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Labcorp Drug Development
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ICON plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evotec
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharmaron
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Crown Bioscience
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Taconic Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• The Jackson Laboratory
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Champions Oncology
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oncodesign Services
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syneos Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Parexel International
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inotiv
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Covance
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Discovery
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MBL International
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Creative Biolabs
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Xentech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations